Nasopharyngeal Carcinoma
Conditions
Keywords
immunotherapy, Anti-PD-1 antibody, Nasopharyngeal Carcinoma, immuno-oncology
Brief summary
This is a multicenter, single-arm open-label, phase II study to evaluate the anti-tumor activity, safety, PK and immunogenicity of AK105 (Anti-PD1 antibody) in patients with metastatic nasopharyngeal carcinoma who have progressed after at least 2 prior lines of systemic chemotherapy (of which one of them must be platinum-based chemotherapy).
Interventions
BIOLOGICALAK105
intravenous (IV) infusion
Sponsors
Akeso Tiancheng, Inc
Akeso
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Signed written informed consent form voluntarily. * Age over 18 years old (inclusive) and not more than 75 years old (inclusive), when signing the ICF. * Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1. * Expected life expectance ≥ 3 months. * Histologically confirmed diagnosis of nonkeratinizing differentiated or undifferentiated NPC. * Not suitable for radical local therapy. * Stage IVb metastatic NPC patients who have failed the first-line platinum-based chemotherapy and the second-line chemotherapy. * At least one measurable tumor lesion per RECIST 1.1 criteria. A lesion previously treated with local therapies such as radiotherapy can be considered a target lesion if there is objective evidence of progression in the lesion. * Subjects must provide an available tumor tissue sample taken within 3 years prior to enrollment. * Adequate organ function. * Females of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception. * Nonsterilized males who are sexually active with a female partner of childbearing potential must use highly effective method of contraception from Day 1 and for 120 days after the last dose of investigational product.
Exclusion criteria
* Receipt of last radiotherapy or any anti-tumor treatment \[chemotherapy, targeted therapy, immunotherapy, Chinese herbal drugs with antitumor indications, or immunomodulators or tumor embolization\] within 4 weeks prior to the first dose of study treatment. Nitrosourea or mitomycin C treatment within 6 weeks prior to the first dose of AK105. * Prior exposure to any anti-PD-1, anti-PD-L1, anti-CTLA-4 antibody, or any other antibody or drug therapy for T cell co-stimulatory or checkpoint pathways, such as ICOS or agonists (e.g. CD40, CD137, GITR and OX40 etc). * Other invasive malignancies within 2 years, except for locally treatable (manifested as cured) malignancies, such as basal or skin squamous cell carcinoma, superficial bladder cancer, cervical or breast carcinoma in situ. * Subjects with active, known or suspected autoimmune disease, or a medical history of autoimmune disease, with the exceptions of the following: vitiligo, alopecia, Grave disease, psoriasis or eczema not requiring systemic treatment within the last 2 years, hypothyroidism (caused by autoimmune thyroiditis) only requiring steady doses of hormone replacement therapy and type I diabetes only requiring steady doses of insulin replacement therapy, or completely relieved childhood asthma that requires no intervention in adulthood, or primary diseases that will not relapse unless triggered by external factors. * Active or previously documented inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis or chronic diarrhea). * Subjects who require systemic corticosteroids (a dose equivalent to \>10 mg/day prednisone) or other immunosuppressive drugs within 14 days prior to the first dose of study drug. * Known history of testing positive for human immunodeficiency virus (HIV). * Known history of primary immunodeficiency virus infection. * Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. * History of gastrointestinal perforation and/ or fistula within 6 months prior to enrollment. * Necrotic lesion(s) found by examinations within 4 weeks prior to enrollment, which, in the investigator's opinion, is at risk of massive bleeding. * Known history of interstitial lung disease. * Known history of active tuberculosis (TB). * Serious infections within 4 weeks prior to the first dose of study drug, including but not limited to complications requiring hospitalization, sepsis or severe pneumonia. * An active infection requiring systemic therapy. * Subjects with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) DNA exceeding 500 IU/ mL or active hepatitis C virus (HCV) should be excluded. Subjects with non-active HBsAg carriers, treated and stable hepatitis B (HBV DNA \<500 IU/ mL) , and cured hepatitis C can be enrolled. Subjects with positive HCV antibodies are eligible only if the HCV RNA test results are negative. * Major surgery (as defined by the investigator) within 30 days prior to the first dose of study drug. * Presence of meningeal metastasis, spinal cord compression, leptomeningeal disease, or active brain metastasis. * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage. * Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v4.03 Grade 0 or 1, or to levels dictated in the inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (ORR) assessed by IRRC per RECIST v1.1 for anti-tumor activity in the Full Analysis Set (FAS) population | up to 2 years | ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease control rate (DCR) as assessed by IRRC and investigator | up to 2 years | DCR is defined as the proportion of subjects with CR, PR, or SD, based on RECIST v1.1. |
| Duration of response (DoR) as assessed by IRRC and investigator | up to 2 years | DoR is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first. |
| Overall survival (OS) | up to 2 years | OS is defined as the time from the date of randomization to death from any cause. |
| Incidence and severity of treatment-emergent adverse events (TEAEs) | From the time of informed consent signed through 90 days after last dose of AK105 | An adverse event (AE) is any untoward medical occurrence or the deterioration of existing medical event in a clinical study subject administered an investigational drug, which does not necessarily have an unequivocal causal relationship with the investigational product. |
| Progression-free survival (PFS) as assessed by IRRC and investigator | up to 2 years | PFS is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) or death from any cause (whichever occurs first). |
| Number of subjects who develop detectable anti-drug antibodies (ADAs) | From first dose of AK105 through 90 days after last dose of AK105 | The immunogenicity of AK105 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs). |
| ORR as assessed by investigator per RECIST v1.1 for anti-tumor activity in the FAS population | up to 2 years | ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1. |
| Time to response (TTR) assessed by IRRC and investigator ； | up to 2 years | TTR is defined as the time from the first dose of study drug to the first documented response (CR or PR). |
| Observed concentrations of AK105 | From first dose of AK105 through 90 days after last dose of AK105 | The endpoints for assessment of PK of AK105 include serum concentrations of AK105 at different timepoints after AK105 administration. |
Countries
China
Outcome results
None listed